A groundbreaking project to study potential HIV vaccines in several African countries has been derailed by an abrupt cut in ...

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...

A new study published in The Lancet HIV reveals gaps in knowledge surrounding the prevention of HPV-related cancers in people living with HIV and outlines future research priorities.

A new study published in The Lancet HIV reveals gaps in knowledge surrounding the prevention of HPV-related cancers in people ...

Protein crystallization at the SER-CAT beamline at Argonne’s Advanced Photon Source proved key to the discovery of a new HIV vaccine candidate.

This research on a T-cell–targeting vaccines in HIV has implications for future study design to incorporate consideration of age and years on antiretroviral therapy (ART) to evaluate the level of ...

A group of leading African researchers trying to develop effective vaccines against HIV is trying to figure out how to ...